Aarti Pharmalabs Ltd has shared its Q2/H1 FY25 Results Presentation which outlines its operations, including 200+ products, 56 patents filed, and a 20% global market share in Xanthine, with a net debt/equity ratio of 0.18x, and an overall turnover of INR 134 billion in FY23.